Situation Assessment

• Fabrus, Inc. is a private biotechnology company focused on the development of novel monoclonal antibodies that merge human IgG scaffolds with ultralong, bovine CDR3s.
• Senesco Technologies, Inc. (OTC BB – SNTI) is a publicly traded cancer therapeutics company with a proprietary platform in eukaryotic translation initiation Factor 5a.
• Fabrus selected Locust Walk Partners as its exclusive business and corporate development advisor to conclude a merger with Senesco.

Key Activities

• Developed in-depth pro-forma and company valuation to guide term negotiations.
• Provided strategic input and quantitative analysis to optimize merger terms.
• Assisted management team during merger negotiations.

Successful Outcome

• Fabrus and Senesco successfully completed a merger. Senesco’s public listing transferred to the NASDAQ following the merger.
• Locust Walk continues to serve as an advisor to the newly formed company, demonstrating Senesco’s ongoing confidence in the value that Locust Walk brings to their organization.